BridgeBio’s lead drug Attruby (acoramidis) is tracking a steep commercial ramp, alongside $500 million share repurchase program and three additional NDAs planned for 2026. Citi’s caution stands ...
BridgeBio Pharma recently filed a New Drug Application with the FDA for encaleret in autosomal dominant hypocalcemia type 1, following Phase 3 CALIBRATE results showing rapid, durable improvements in ...
Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Investing.com - Evercore ISI raised its price target on BridgeBio Pharma stock (NASDAQ:BBIO) to $130 from $125 while maintaining an Outperform rating. The stock currently trades at $67.45, delivering ...
BridgeBio reported $195 million in total first-quarter revenue. Heart drug Attruby accounted for nearly $181 million in sales, representing 24% growth from the fourth quarter and 392% year-over-year ...
$194.5 million in total first quarter revenues, comprised of $180.6 million of U.S. Attruby® net product revenue, with strong prescribing growth and patient persistence driving continued commercial ...
We just covered Billionaire Tom Steyer’s 10 Stock Picks with Huge Upside Potential and BridgeBio Pharma, Inc. (NASDAQ:BBIO) ranks 2nd on this list. BridgeBio Pharma, Inc. (NASDAQ:BBIO) is a relatively ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
- New national campaign encourages recognition of ATTR-CM, often mistaken for other heart conditions, where earlier diagnosis and treatment may help improve outcomes1 "In clinical practice, ATTR-CM is ...
Osteoarthritis affects around 600 million people globally. It causes pain, stiffness and reduced joint function – most commonly in the knees, hands and hips. There’s currently no cure for ...
Knee osteoarthritis is a complex disease that affects the whole joint, including bone, cartilage, ligaments and muscles. Osteoarthritis is a common cause of pain and movement difficulty, affecting 8.3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results